Exosome-based therapy targets squamous cell carcinomas that are drug-resistant and offers new hope for patients with drug-resistant cancers

Exosome-based therapy targets squamous cell carcinomas that are drug-resistant and offers new hope for patients with drug-resistant cancers

The first two blood cancer patients in a US-based trial, who had suffered relapses despite having treatment, have now been in remission for up to 120...

The 3D Urology and Prostate Clinics introduce their groundbreaking 3D Prostate Cancer Targeted Treatment, offering innovative and effective solutions...

Researchers at the Medical College of Georgia at Augusta University, USAm are searching for a better way to understand why many men with prostate...

A treatment paradox has recently come to light in prostate cancer: Blocking testosterone production halts tumour growth in early disease while...

Cleo Commences U.S. Clinical Trials Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to...

September 8, 2024 -- Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca’s...

September 8, 2024 -- Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca’s...

HOUSTON, Sept. 9, 2024. Moleculin Biotech, Inc., ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio...